More data, this time from a large observational study, are bolstering the idea that glucagon-like peptide-1 (GLP-1) receptor ...

Biogen joins major drugmakers such as Eli  Lilly, Roche and Merck, who have all announced investments in the U.S. as the industry braces for potential import levies. Drugs have so far been exempt from ...

Trump’s budget proposal, from May, seeks to slash the Department of Health and Human Services’ budget by $31.3 billion ...

Eli Lilly outpaces Novo in the GLP-1 market with Tirzepatide and emerging blockbusters, signaling future growth. Read more on ...

GE HealthCare Technologies' market position, rising earnings, and improving financials make it an attractive investment opportunity. Read more on GEHC stock.

Since starting operations in North Carolina 30 years ago, Biogen has spent approximately $10 billion to bolster its ...